Holman Rury R
Diabetes Trials Unit, OCDEM, University of Oxford, Oxford OX3 7LJ, UK.
Metabolism. 2006 May;55(5 Suppl 1):S2-5. doi: 10.1016/j.metabol.2006.02.006.
The United Kingdom Prospective Diabetes Study shows sulfonylureas to be an effective first-line therapy for people with type 2 diabetes mellitus. The durability of the glycemic control obtained is dependent on the degree to which beta-cell function can be maintained, but sulfonylureas appear neither to increase nor to decrease the underlying rate of loss of beta-cell function. As sulfonylureas act by enhancing insulin secretion, they are probably best used close to the time when diabetes is diagnosed when beta-cell function is at its greatest and their utility can be extended by judicious use in combination with agents that improve glycemia by different modes of action, including insulin.
英国前瞻性糖尿病研究表明，磺脲类药物是2型糖尿病患者有效的一线治疗药物。所获得的血糖控制的持久性取决于β细胞功能能够维持的程度，但磺脲类药物似乎既不会增加也不会降低β细胞功能的潜在丧失率。由于磺脲类药物通过增强胰岛素分泌起作用，它们可能最适合在糖尿病诊断时使用，此时β细胞功能处于最佳状态，并且通过与包括胰岛素在内的以不同作用方式改善血糖的药物联合合理使用，可以扩大其效用。
